Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.07 (0.89%)

Market Cap$111,865,980

07/19/18  1:15 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $7.93 with a 52 week high of $21.59 and a 52 week low of $4.75.

Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients


Read More

Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD


Read More

Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update


Read More

There are currently no events scheduled.